Updated Jul 16, 2026
Crystal Adam has filed 3 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $4.99M.
Crystal Adam is associated with Tango Therapeutics, Inc., as indicated by recent SEC filings. Further details about her specific role or contributions to the company are not readily available in public records.
| Role | Insider |
|---|---|
| Notability | 10/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | TNGX | Tango Therapeutics, Inc. | S — Open-market sale | 7.4K | $30.25 | $223K |
| 2026-07-02 | TNGX | Tango Therapeutics, Inc. | S — Open-market sale | 19.6K | $29.34 | $576K |
| 2026-07-02 | TNGX | Tango Therapeutics, Inc. | M — Option exercise | 27.0K | $5.20 | $140K |
| 2026-06-03 | TNGX | Tango Therapeutics, Inc. | S — Open-market sale | 20.9K | $23.06 | $481K |
| 2026-06-03 | TNGX | Tango Therapeutics, Inc. | S — Open-market sale | 6.1K | $22.25 | $137K |
| 2026-06-03 | TNGX | Tango Therapeutics, Inc. | M — Option exercise | 27.0K | $5.20 | $140K |
| 2026-05-05 | TNGX | Tango Therapeutics, Inc. | S — Open-market sale | 1.1K | $22.00 | $24K |
| 2026-05-05 | TNGX | Tango Therapeutics, Inc. | S — Open-market sale | 25.9K | $21.19 | $549K |
| 2026-05-05 | TNGX | Tango Therapeutics, Inc. | M — Option exercise | 27.0K | $5.20 | $140K |
| 2026-04-17 | TNGX | Tango Therapeutics, Inc. | S — Open-market sale | 38.5K | $25.00 | $962K |
| 2026-04-17 | TNGX | Tango Therapeutics, Inc. | M — Option exercise | 38.5K | $5.20 | $200K |
| 2026-04-03 | TNGX | Tango Therapeutics, Inc. | S — Open-market sale [10b5-1] | 27.0K | $21.20 | $572K |
| 2026-04-03 | TNGX | Tango Therapeutics, Inc. | M — Option exercise [10b5-1] | 27.0K | $5.20 | $140K |
| 2026-03-28 | TNGX | Tango Therapeutics, Inc. | S — Open-market sale [10b5-1] | 12.0K | $20.11 | $241K |
| 2026-03-28 | TNGX | Tango Therapeutics, Inc. | M — Option exercise [10b5-1] | 12.0K | $5.20 | $62K |
| 2026-03-09 | TNGX | Tango Therapeutics, Inc. | S — Open-market sale [10b5-1] | 20.3K | $15.00 | $304K |
| 2026-02-27 | TNGX | Tango Therapeutics, Inc. | S — Open-market sale [10b5-1] | 54.3K | $12.77 | $694K |
| 2026-02-05 | TNGX | Tango Therapeutics, Inc. | S — Open-market sale | 201 | $12.90 | $3K |
| 2026-02-05 | TNGX | Tango Therapeutics, Inc. | S — Open-market sale | 18.3K | $12.26 | $224K |
| 2026-02-05 | TNGX | Tango Therapeutics, Inc. | A — Grant or award | 47.5K | $0.00 |
Crystal Adam is associated with Tango Therapeutics, Inc., as indicated by recent SEC filings. Further details about her specific role or contributions to the company are not readily available in public records.…
3 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 13 open-market sales ($4.99M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Crystal Adam profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.